OPTH

New wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across AustraliaVANCOUVER, British Columbia, Oct.

Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial to evaluate efficacy and safety of two sessions of…

VANCOUVER, British Columbia, Oct.

Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies Seasoned finance executive brings more than 25 years of leadership experience across…

Optimi Health (OPTI.CN) said Wednesday it completed a production batch of 5-mg naturally derived psi

One cGMP batch, manufactured in-house under Optimi's Health Canada Drug Establishment Licence, supplies both the Canadian trial and Australian clinics One cGMP batch, manufactured in-house under Optimi's Health Canada Drug Establishment Licence, supplies both…

Supports Optimi’s planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSD Supports Optimi’s planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSD

Shares of Optimi Health Corp. and other commercial manufacturers of MDMA and psilocybin are in focus, following federal administrative actions, a public hearing on psychedelic medicines, and an old endorsement of these drugs by tech billionaire Elon Musk.

Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up…

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp.